- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Angus Worthing: Congressional Budget Allocation for Healthcare
Angus Worthing, MD, FACR, FACP, discusses the need for adequate funding for the FDA and healthcare.
Transcript:
Former CMS head Andy Slavitt recently spoke about the need for a “champion” in Congress who can ensure sufficient budget allocation for healthcare. Do you agree?
I do, I think Andy Slavitt has a lot of good ideas about healthcare reform in the US. I think we do need champions in Congress right now to help fix the system. One important part, as we talk about biosimilars, is that we need to support the Food and Drug Administration as it hires experts that are needed to both review and approve safe and effective drugs—that’ll be biosimilars that we use, but also that will create guidances for manufacturers to come up with the right clinical trials and clinical trial designs to prove and give confidence to doctors and patients that the drugs work effectively. So, I think it’s important to fund the agency appropriately and we need champions in Congress to do that. Fortunately, this Congress has already authorized the Biosimilar User Fee Agreement of 2017, and the President signed it into law. So, that’s an important first step to that process.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
